Gershkevitsh Eduard, Clark Catharine H, Staffurth John, Dearnaley David P, Trott Klaus-Rüdiger
Department of Radiotherapy, Cancer Center, North-Estonian Regional Hospital, Tallinn, Estonia.
Strahlenther Onkol. 2005 Mar;181(3):172-8. doi: 10.1007/s00066-005-1360-4.
To investigate the dose distribution in active bone marrow of patients undergoing intensity-modulated radiotherapy (IMRT) for prostate cancer and compare it to the distribution in the same patients, if they had been treated using conformal plans, in order to develop criteria for optimization to minimize the estimated risk of secondary leukemia.
Mean bone marrow doses were calculated for ten patients with localized prostate cancer who underwent whole-pelvis IMRT and compared to three-dimensional conformal (3-D CRT) plans prepared for the same patients. Also for comparison, the IMRT and 3-D CRT plans were produced to simulate the treatment of the prostate gland only. To measure the dose to extrapelvic bone marrow, three thermoluminescent diode (TLD) chips were placed in the middle of the sternum region inside the Rando phantom.
For both the pelvic and prostate-only volumes, the IMRT plans were superior to 3-D CRT plans in reducing the high dose volume to the rectum, the bladder and the small bowel while maintaining acceptable coverage of the planning target volume (PTV). For the pelvic treatment group the IMRT plans, compared to 3-D CRT, reduced the high dose volume (> 20 Gy) to os coxae, which is the main contributor of dose to pelvic bone marrow, but increased the middle dose volume (10-20 Gy). No statistically significant differences were observed for lower dose volumes (< 5 Gy). For the prostate-only treatment the IMRT plan increased the high dose volume and slightly decreased the low dose volume of pelvic bone marrow. However, for both treatments the leakage dose to extrapelvic sites was higher by a factor of 2 in IMRT plans.
There are significant differences in the dose-volume histograms of bone marrow doses from 3-D CRT and from IMRT. Pronounced dose inhomogeneity reduces the risk of leukemia compared to homogeneous radiation exposure of the bone marrow. The mean bone marrow dose is therefore not a useful criterion to judge plan quality, since scattered low doses to distant sites may be more critical than the high dose volumes receiving > 10 Gy. The number of monitor units needed to deliver an IMRT plan affects leakage dose and their incorporation into planning constraints should be considered.
研究接受前列腺癌调强放疗(IMRT)患者活性骨髓内的剂量分布,并将其与这些患者若采用适形放疗计划时的剂量分布进行比较,以制定优化标准,将继发性白血病的估计风险降至最低。
计算了10例接受全盆腔IMRT的局限性前列腺癌患者的平均骨髓剂量,并与为同一患者制定的三维适形(3-D CRT)计划进行比较。同样为了进行比较,还制定了IMRT和3-D CRT计划来模拟仅对前列腺进行治疗的情况。为测量盆腔外骨髓的剂量,在Rando体模内胸骨区域中部放置了3个热释光二极管(TLD)芯片。
对于盆腔和仅前列腺区域,IMRT计划在减少直肠、膀胱和小肠的高剂量体积方面优于3-D CRT计划,同时保持了计划靶体积(PTV)的可接受覆盖范围。对于盆腔治疗组,与3-D CRT相比,IMRT计划减少了对髋骨的高剂量体积(>20 Gy),髋骨是盆腔骨髓剂量的主要贡献者,但增加了中剂量体积(10 - 20 Gy)。对于较低剂量体积(<5 Gy)未观察到统计学显著差异。对于仅前列腺治疗,IMRT计划增加了盆腔骨髓的高剂量体积并略微降低了低剂量体积。然而,对于两种治疗,IMRT计划中盆腔外部位的漏射剂量高出2倍。
3-D CRT和IMRT的骨髓剂量剂量体积直方图存在显著差异。与骨髓均匀辐射暴露相比,明显的剂量不均匀性降低了白血病风险。因此,平均骨髓剂量不是判断计划质量的有用标准,因为远处部位的散射低剂量可能比接受>10 Gy的高剂量体积更关键。实施IMRT计划所需的监测单位数量会影响漏射剂量,应考虑将其纳入计划约束条件。